Table 2. Multivariate analysis for lymph node positivity and advanced nodal stage.
| Characteristic | Lymph node positivity | Advanced nodal stage* | ||||
|---|---|---|---|---|---|---|
| Odds ratio | Standard error | p-value | Odds ratio | Standard error | p-value | |
| Age | 0.986 | 0.002 | < 0.001 | 1.013 | 0.004 | 0.005 |
| Race | ||||||
| White | Reference | 0.081 | Reference | 0.786 | ||
| Asian | 0.89 | 0.109 | 0.287 | 0.95 | 0.208 | 0.807 |
| Black | 1.254 | 0.1 | 0.024 | 0.967 | 0.19 | 0.859 |
| Tumor size | 1.052 | 0.002 | < 0.001 | 1.032 | 0.003 | < 0.001 |
| Tumor grade | 1.433 | 0.045 | < 0.001 | 1.357 | 0.09 | 0.001 |
| Cancer subtype | ||||||
| HR+/HER2- | Reference | 0.040 | Reference | 0.439 | ||
| HR+/HER2+ | 0.927 | 0.11 | 0.491 | 1.009 | 0.198 | 0.966 |
| HR-/HER2+ | 0.928 | 0.223 | 0.739 | 1.355 | 0.331 | 0.359 |
| HR-/HER2- | 0.686 | 0.132 | 0.004 | 0.744 | 0.244 | 0.226 |
HR=hormone receptor; HER2=human epidermal growth factor receptor 2.
*American Joint Committee on Cancer stage N2-3.